FRTY - ETF AI Analysis
Top Page
Alger Mid Cap 40 ETF (FRTY)
FRTY, the Alger Mid Cap 40 ETF, has a solid overall rating driven by strong performers like Comfort Systems USA and Okta, which bring robust revenue growth, good cash flow management, and positive momentum to the portfolio. However, weaker holdings such as Twist Bioscience and Nebius Group, which face profitability and cash flow challenges and signs of overvaluation, weigh on the fund’s quality. The main risk factor is exposure to several companies with high valuations and financial instability, which could increase volatility if growth expectations are not met.
FRTY vs. SPDR S&P 500 ETF (SPY)
- AUM
- 141.03M
- Region
- North America
- Expense Ratio
- 0.60%
- Beta
- 1.35
- Issuer
- Alger
- Inception Date
- Feb 26, 2021
- Dividend Yield
- 0.19%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
FRTY Summary
The Alger Mid Cap 40 ETF (FRTY) is a fund that invests in about 40 medium‑sized U.S. companies that are focused on growth. It doesn’t track a set index, but instead follows a mid‑cap growth theme, choosing firms in areas like technology, industrials, and health care. Well‑known names in the fund include Cloudflare and Axon Enterprise. Someone might invest in FRTY to seek higher growth than large, slower‑moving companies and to diversify beyond big blue‑chip stocks. A key risk is that mid‑cap growth stocks can be more volatile, so the ETF’s value can rise and fall sharply with the market.
How much will it cost me?
This ETF has an expense ratio of 0.60%, which means you’ll pay about $6 per year for every $1,000 invested. That’s higher than the average ETF cost because it’s actively managed, with professionals selecting a focused portfolio of mid-cap growth stocks instead of simply tracking an index.
What would affect this ETF?
FRTY could benefit if the U.S. economy stays healthy and innovation in technology and health care continues, helping its mid-sized growth companies like Cloudflare, Snowflake, and Biogen expand. On the downside, higher interest rates, slower economic growth, or tighter health care and tech regulations could hurt these growth-focused U.S. stocks, and the fund’s concentrated portfolio means setbacks in a few key holdings may have a bigger impact.
FRTY Top 10 Holdings
FRTY is leaning hard into innovative U.S. mid-cap growth, with health care and cloud-focused tech setting the tone. Twist Bioscience and Guardant Health have been rising, giving the fund a strong biotech heartbeat, while Cloudflare and Snowflake add momentum from the data and cybersecurity side, though their profitability issues can make the ride bumpy. Comfort Systems and Monolithic Power provide steadier industrial and chip exposure, helping balance the more volatile names. On the flip side, Liberty Formula One and Heico have been lagging lately, quietly tugging on overall returns.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 RGEN | Repligen | 4.81% | $6.79M | $11.36B | 13.53% | 68Neutral |
 TWST | Twist Bioscience | 4.76% | $6.71M | $9.39B | 336.16% | 43Neutral |
 FWONK | Liberty Media Liberty Formula One | 4.67% | $6.59M | $22.98B | -6.78% | 66Neutral |
 SNPS | Synopsys | 4.37% | $6.17M | $86.46B | -7.00% | 73Outperform |
 NET | Cloudflare | 3.74% | $5.27M | $103.86B | 44.08% | 61Neutral |
 SNOW | Snowflake | 3.61% | $5.09M | $113.86B | 29.91% | 54Neutral |
 HEI.A | Heico Cp Cl A | 3.41% | $4.81M | $35.59B | -6.12% | 79Outperform |
 OKTA | Okta | 3.36% | $4.75M | $33.92B | 131.31% | 75Outperform |
 GH | Guardant Health | 3.30% | $4.66M | $22.37B | 139.51% | 61Neutral |
 BIIB | Biogen | 3.09% | $4.36M | $35.61B | 71.84% | 74Outperform |
FRTY Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FRTY, the sentiment is Negative. The current price of 21.48 is below the 20-day moving average (MA) of 23.07, below the 50-day MA of 22.96, and below the 200-day MA of 21.99, indicating a neutral trend. The MACD of -0.31 indicates Positive momentum. The RSI at 44.34 is Neutral, neither overbought nor oversold. The STOCH value of 24.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FRTY.
FRTY Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FRTY | $21.48 | $24.00(11.76% Upside) | $141.03M | 0.60% | 60Neutral |
 AVMV | $79.56 | $93.47(17.49% Upside) | $798.53M | 0.20% | 71Outperform |
 AVMC | $78.70 | $94.71(20.34% Upside) | $520.44M | 0.18% | 70Outperform |
 GLRY | $36.25 | $49.68(37.04% Upside) | $157.53M | 0.80% | 74Outperform |
 TMFM | $22.39 | $27.49(22.76% Upside) | $109.45M | 0.85% | 67Neutral |
 ACMG | $69.94 | $89.83(28.44% Upside) | $103.40M | 0.39% | 70Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FRTY | Alger Mid Cap 40 ETF | 21.48 | -0.95 | -4.23% | |
| AVMV | Avantis U.S. Mid Cap Value ETF | 79.56 | 11.45 | 16.80% | |
| AVMC | Avantis U.S. Mid Cap Equity ETF | 78.70 | 9.53 | 13.78% | |
| GLRY | Inspire Faithward Mid Cap Momentum ESG ETF | 36.25 | -1.23 | -3.28% | |
| TMFM | Motley Fool Mid-Cap Growth ETF | 22.39 | -2.53 | -10.17% | |
| ACMG | American Century Mid Cap Growth Insights ETF | 69.94 | 1.23 | 1.80% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.